Indication
Advanced Solid Tumours
20 clinical trials
43 products
Product
DurvalumabClinical trial
A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)Status: Active (not recruiting), Estimated PCD: 2023-04-28
Product
AZD8701Product
CeralasertibProduct
RC88Clinical trial
An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid TumoursStatus: Recruiting, Estimated PCD: 2024-06-01
Product
FPI-1547Product
[225Ac]-FPI-1434Product
FPI-1175Product
[225Ac]-FPI-1434 InjectionClinical trial
A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2023-10-20
Product
AZD9592Clinical trial
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-29
Product
5-FluorouracilProduct
BevacizumabProduct
OsimertinibProduct
LeucovorinProduct
SintilimabClinical trial
An Open-label, Non-randomised, Multi-center Study to Evaluate the Safety， and Efficacy Off RC88 Combined With Sintilimab in AdvancedSolid TumoursStatus: Recruiting, Estimated PCD: 2025-05-01
Product
RXC004Clinical trial
A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of CareStatus: Completed, Estimated PCD: 2023-11-30
Product
DenosumabProduct
pembrolizumabProduct
AZD9150Clinical trial
A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2020-01-17
Product
5-FlourouracilProduct
GemcitabineProduct
CisplatinProduct
CarboplatinProduct
Nab-paclitaxelProduct
AZD1775Product
MEDI4736Clinical trial
A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2019-04-22
Product
FluorouracilProduct
Folinic AcidClinical trial
A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-10-01
Product
IMP4297(senaparib)Product
AdavosertibClinical trial
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor), Rifampicin (a CYP3A4 Inducer), and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients With Advanced Solid TumoursStatus: Terminated, Estimated PCD: 2022-06-01
Product
RifampicinProduct
ItraconazoleProduct
OmeprazoleProduct
AZD0156Product
OlaparibProduct
irinotecanClinical trial
A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2019-09-13
Product
EXS21546Clinical trial
A Phase 1B/2A Study to Assess the Safety, Tolerability, Pharmacokinetic and Anti-tumoral Activity of EXS21546 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid TumoursStatus: Terminated, Estimated PCD: 2023-09-27
Product
PM1021Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PM1021 (Anti-TIGIT) Monotherapy and PM1021 in Combination With PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid TumoursStatus: Not yet recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid TumourStatus: Active (not recruiting), Estimated PCD: 2022-04-01
Clinical trial
A Phase II Multi-Centre Study Evaluating the Efficacy of Dacomitinib for Patients With Epidermal Growth Factor Receptor (EGFR)-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expression or Other Novel Emerging BiomarkersStatus: Recruiting, Estimated PCD: 2025-07-01
Product
DacomitinibClinical trial
A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2026-06-11
Product
EBC-129Product
PembrolizumabClinical trial
A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced MalignanciesStatus: Not yet recruiting, Estimated PCD: 2029-11-01
Product
UCB4594Clinical trial
A Cancer Research UK Phase I/IIa Clinical Trial of BT1718, (A Bicycle Drug Conjugate) Given Intravenously in Patients With Advanced Solid Tumours.Status: Completed, Estimated PCD: 2023-11-20
Product
BT1718